Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses the increased infection risk in patients with multiple myeloma (MM) who are treated with immunotherapy. He highlights the bias in infection reporting in clinical trials and suggests recording infections per patient per month and accounting for varying study durations to improve accuracy. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
